Bioglutide
Summary
Bioglutide (NA-931) is an investigational oral agent that Biomed Industries describes as a quadruple IGF-1/GLP-1/GIP/glucagon receptor agonist for weight loss. No peer-reviewed pharmacology, structure, or trial results exist; the only public records are three sponsor-run ClinicalTrials.gov registrations, and those registrations contain documented irregularities. Every efficacy claim for NA-931 is currently unverifiable.
Also known as: NA-931, NA931, NA 931
Key Findings at a Glance
- • PubMed contains zero publications mentioning NA-931 or bioglutide, and no molecular structure, formula, sequence, or CAS number has ever been publicly disclosed.
- • Three sponsor-run ClinicalTrials.gov registrations exist: a completed Phase 1 (74 participants), a completed Phase 2 (126 participants), and a not-yet-recruiting Phase 2 combination with tirzepatide.
- • No results have been posted or published for any registered trial, so no efficacy or safety claim can be independently verified.
- • The ClinicalTrials.gov records carry documented registration irregularities, including Phase 2 eligibility criteria virtually identical to Viking Therapeutics' earlier VK2735 trial registration.
Bioglutide Overview & Molecular Profile
Bioglutide (NA-931) is a compound under development by Biomed Industries, Inc., which describes it as an oral, once-daily quadruple receptor agonist targeting the IGF-1, GLP-1, GIP, and glucagon receptors for weight loss. No peer-reviewed publication describes NA-931's structure, pharmacology, or clinical effects: PubMed contains zero papers mentioning it, and no molecular formula, sequence, molecular weight, or CAS number has been disclosed in any public scientific source. The public record consists of three ClinicalTrials.gov registrations: a Phase 1 study (NCT06615700, 74 participants, listed as completed), a Phase 2 study (NCT06564753, 126 participants, listed as completed in April 2025 with no results posted), and a second Phase 2 combination study with tirzepatide (NCT06732245, not yet recruiting as of late 2026). Two irregularities are visible in the registry records themselves: the Phase 1 study was registered retrospectively, first posted on 2024-09-27, nearly five months after its own recorded start date of 2024-05-06 and two months after the Phase 2 trial had begun on 2024-07-19; and the Phase 2 eligibility criteria are virtually word-for-word identical to those of Viking Therapeutics' earlier VK2735 Phase 2 registration (NCT06068946, first posted 2023-10-05). These facts do not prove the underlying work is invalid, but they mean no claim about bioglutide can be independently verified at this time.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
According to its sponsor, NA-931 is a quadruple receptor agonist engaging the insulin-like growth factor 1 (IGF-1), glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. GLP-1, GIP, and glucagon receptor agonism are established weight-loss mechanisms, combined in verified agents such as retatrutide, but adding IGF-1 receptor activity to an incretin-type molecule would be pharmacologically unusual and has no precedent in the peer-reviewed literature. Because no primary pharmacology has been published, the claimed mechanism cannot be evaluated: there are no receptor binding data, no signaling assays, no animal studies, and no human pharmacodynamic measurements in any public scientific source. The registrations describe NA-931 as orally administered once daily; if it is a peptide, as its name and categorization imply, achieving useful oral bioavailability would itself be a significant pharmaceutical claim requiring published evidence, since the only verified oral agents in this class are non-peptide small molecules such as orforglipron or specially formulated peptides.
Research-Observed Effects
Weight Loss (Sponsor-Claimed)
Preliminary ResearchBiomed Industries claims NA-931 produces weight loss through quadruple receptor agonism and has registered a completed 126-participant Phase 2 trial in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. No results from that trial have been posted to the registry or published in any peer-reviewed venue, so neither the magnitude nor the durability of any weight-loss effect can be stated. No independent laboratory has published confirmatory data in any species, and no preclinical efficacy data exists in the public literature.
Glycemic Control (Sponsor-Claimed)
Preliminary ResearchThe sponsor's Phase 1 registration included a multiple-dose cohort in patients with type 2 diabetes, and the claimed GLP-1, GIP, and glucagon receptor activity would be expected to influence glucose homeostasis based on established class pharmacology. However, no glucose, insulin, or HbA1c data for NA-931 has been published anywhere, so this application rests entirely on extrapolation from other incretin-class agents with verified pharmacology.
Oral Administration (Unverified Claim)
Preliminary ResearchNA-931 is described in its trial registrations as an oral, once-daily agent. Oral delivery of peptide-class incretin agonists is a known pharmaceutical challenge that has been solved only with specialized formulations (for example, the SNAC absorption enhancer in oral semaglutide) or by switching to non-peptide small molecules. No formulation, stability, or bioavailability data for NA-931 has been disclosed in any scientific source, so the oral dosing claim cannot be independently assessed.
Safety & Tolerability
There is no published safety data for bioglutide (NA-931) in any species. The sponsor lists two completed early-phase trials, but no adverse-event results have been posted or published, and the compound's molecular identity has never been disclosed, so no safety assessment is possible.
Human data: Sponsor registrations list a completed Phase 1 (74 participants) and a completed Phase 2 (126 participants), but zero human outcome or adverse-event data has been posted to the registry or published in any peer-reviewed venue. Human exposure and tolerability are unverifiable from the public record.
Regulatory status: Not approved by any regulator. No CAS number, no PubChem record, no published structure. ClinicalTrials.gov registrations NCT06615700, NCT06564753, and NCT06732245, all sponsor-run by Biomed Industries, are the only public records.
-
No peer-reviewed safety, tolerability, or adverse-event data has been published for NA-931 in humans or in animals; its safety profile is entirely uncharacterized in the public literature.
Theoretical -
Because no molecular structure, formula, sequence, or CAS number has been disclosed, third-party laboratories cannot verify the identity or purity of any material sold as NA-931, making gray-market exposure an unquantifiable risk.
Theoretical
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Bioglutide is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Oral (sponsor registrations) | 150 mg (one registered level) | Once daily | From NCT06732245 registration; no published PK or efficacy data |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 (NCT06615700)
Biomed Industries, Inc.
ClinicalTrials.gov (2024)
A randomized, double-blind, placebo-controlled, dose-escalation, first-in-human registration describing single and multiple-ascending doses of NA-931 in overweight or obese participants and multiple doses in patients with type 2 diabetes. Listed as completed with 74 participants. No results have been posted to the registry and no publication exists in PubMed. The registry record shows retrospective registration: it was first posted on 2024-09-27, nearly five months after the study's own recorded start date of 2024-05-06 and two months after the sponsor's Phase 2 trial had begun.
Phase 2 Trials of NA-931 in Subjects Who Are Obese With at Least One Weight-Related Comorbidity (NCT06564753)
Biomed Industries, Inc.
ClinicalTrials.gov (2024)
A randomized, double-blind, placebo-controlled, parallel-arm Phase 2 registration in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. Listed as completed in April 2025 with 126 participants; no results have been posted or published. The eligibility criteria in this registration are virtually word-for-word identical to those of Viking Therapeutics' VK2735 Phase 2 registration (NCT06068946), which was first posted eleven months earlier on 2023-10-05.
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (NCT06732245)
Biomed Industries, Inc.
ClinicalTrials.gov (2024)
A Phase 2 registration evaluating oral NA-931 (150 mg daily) alone and combined with subcutaneous weekly tirzepatide in an estimated 224 adults with overweight or obesity. Listed as not yet recruiting with a planned start of August 2026. Its title and structure closely track Eli Lilly's registration NCT05616013, 'Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese', and its exclusion criteria bar anyone with a history of, or known hypersensitivity to, monoclonal antibody drugs. Bimagrumab is a monoclonal antibody, so that criterion is pharmacologically meaningful in the Lilly trial but not in a study of NA-931 and tirzepatide, which are both peptides. No supporting peer-reviewed data exists.
Frequently Asked Questions
Is bioglutide (NA-931) a real drug?
NA-931 is a compound name associated with three sponsor-run ClinicalTrials.gov registrations by Biomed Industries, Inc. Beyond those registrations there is no verifiable scientific record: no peer-reviewed publications, no disclosed molecular structure, no CAS registry number, and no PubChem entry. Whether the compound's pharmacology has been genuinely characterized cannot be determined from public sources.
What receptors does bioglutide target?
The sponsor describes NA-931 as a quadruple receptor agonist engaging IGF-1, GLP-1, GIP, and glucagon receptors. This is an unverified claim: no binding assays, signaling data, or pharmacology papers have been published, so the receptor profile cannot be independently confirmed. The IGF-1 component in particular has no precedent among verified incretin-class weight-loss agents.
Has bioglutide been tested in humans?
The sponsor's registry listings show a completed Phase 1 study (74 participants) and a completed Phase 2 study (126 participants, listed as completed in April 2025). No results, adverse-event data, or publications have been posted for either. Registration of a trial is not evidence that results exist, and no efficacy or safety conclusion can be drawn from the public record.
Why is bioglutide's trial data flagged as unverified?
The registry records themselves carry three irregularities: the Phase 1 study was registered retrospectively, first posted on 2024-09-27, nearly five months after its own recorded 2024-05-06 start date and two months after the Phase 2 trial began; the Phase 2 eligibility criteria are virtually word-for-word identical to Viking Therapeutics' earlier VK2735 Phase 2 registration; and the tirzepatide combination protocol tracks Eli Lilly's bimagrumab registration NCT05616013, carrying over an exclusion criterion for monoclonal antibody hypersensitivity that makes sense only for an antibody drug. No structure, sequence, or pharmacology has ever been disclosed, so third parties cannot identify or verify the compound.
Is bioglutide FDA approved or available for purchase?
No. NA-931 is not approved anywhere and no verified supply chain exists. Because the molecular identity of NA-931 has never been publicly disclosed, any vendor selling material labeled 'bioglutide' or 'NA-931' cannot be selling a verifiable version of the sponsor's compound, and such material carries unquantifiable risk.
Related Peptides
View allRetatrutide (Triple Agonist)
Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the most profound metabolic effects seen in obesity research to date.
Tirzepatide (GLP-1/GIP)
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research.
Orforglipron
Orforglipron is an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly and approved by the FDA in April 2026 as Foundayo for chronic weight management. It enables once-daily oral dosing of a small molecule that mimics incretin hormone activity, without the food and water restrictions of oral peptide GLP-1 drugs.
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist based on an oxyntomodulin analog, developed by Innovent Biologics in partnership with Eli Lilly, and the first drug of its class to receive regulatory acceptance for obesity in China.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.